Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer.
MetadataShow full item record
Background: This article presents the methodology for tissue sample collection in Trans-CHHiP, the main translational study within the CHHiP (Conventional or Hypofractionated High dose intensity modulated radiotherapy in Prostate cancer, ISRCTN 97182923) trial. The CHHiP trial randomised 3216 men with localised prostate cancer to 3 different radiotherapy fractionation schedules. Trans-CHHiP aims to identify biomarkers of fraction sensitivity. Methods: We outline the process of tissue collection, including central review by a study-specific specialist uropathologist and comparison of the centrally-assigned Gleason grade group with that assigned by the recruiting-centre pathologist. Results: 2047 patients provided tissue from 107 pathology departments between August 2012 and April 2014. A highly motivated Clinical Trials Unit chasing samples and a central Trans-CHHiP group that regularly reviewed progress were important for successful sample collection. Agreement in Gleason grade group assigned by the recruiting centre pathologist and the central study-specific uropathologist occurred in 886 out of 1854 (47.8%) cases. Key lessons learned were the need for prospective consent for tissue collection when recruiting patients to the main trial, and the importance of Material Transfer Agreement (MTA) integration into the initial trial site agreement. Conclusions: This methodology enabled collection of 2047 patient samples from a large randomised radiotherapy trial. Central pathological review is important to minimise subjectivity in Gleason grade grouping and the impact of grade shift.
Version of record
BATS, Blood and Tissue Samples database
BIDD, Biomarker and Imaging Discovery and Development Committee
CHHiP, Conventional or Hypofractionated High dose intensity modulated radiotherapy in Prostate cancer
CRN, Clinical Research Network
CTU, Clinical Trials Unit
H&E, Haematoxylin and Eosin
ICR-CTSU, Institute of Cancer Research Clinical Trials and Statistics Unit
ISUP, International Society of Urological Pathology
MTA, Material Transfer Agreement
NCCN, National Comprehensive Cancer Network
NCRI, National Cancer Research Institute
NHS, National Health Service
Prostate cancer biopsies
Sample collection methodology
TMA, Tissue microarray
TMG, Trial Management Group
TSC, Trial Steering Committee
TURP, Trans-urethral resection of prostate
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Clinical Academic Radiotherapy (Dearnaley)
License start date
Clin Transl Radiat Oncol, 2018, 10 pp. 1 - 6
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; Bliss, JM (2017-11-23)BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking ...
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010) Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; Snowdon, C; Macpherson, I; Wardley, A; Roylance, R; Baird, R (2017-05-08)
A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and 2 pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial 3 4 Tutt, A; Tovey, H; Cheang, M; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, J; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, M; Hoadley, K; Parikh, J; Parker, P; Perou, C; Roylance, R; Shah, V; Shaw, A; Smith, I; Timms, K; Wardley, A; Wilson, G; Gillet, C; Lanchbury, J; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, S; Bliss, J